8 July 2019 in Nature Immunology
16 October 2018 in Nature Communications
Functional CD8+T cells in human tumors play a clear role in clinical prognosis and response to immunotherapeutic interventions. PD-1 expression in T cells involved in chronic infections and tumors such as melanoma often correlates with a state of T-cell exhaustion. Here we interrogate CD8+tumor-infiltrating lymphocytes (TILs) from human breast and melanoma tumors to explore their functional state. Despite expression of exhaustion hallmarks, such as PD-1 expression, human breast tumor CD8+TILs retain robust capacity for production of effector cytokines and degranulation capacity. In contrast, melanoma CD8+TILs display dramatic reduction of cytokine production and degranulation capacity. We show that CD8+TILs from human breast tumors can potently kill cancer cells via bi-specific antibodies. Our data demonstrate that CD8+TILs in human breast tumors retain polyfunctionality, despite PD-1 expression, and suggest that they may be harnessed for effective immunotherapies.
3 October 2019 in JCI Insight
CD8 + tumor-infiltrating lymphocytes (TILs) correlate with relapse-free survival (RFS) in most cancer types, including breast cancer. However, subset composition, functional status, and spatial location of CD8 + TILs in relation to RFS in human breast tumors remain unclear. Spatial tissue analysis via quantitative immunofluorescence showed that infiltration of CD8 + T cells into cancer islands was more significantly associated with RFS than CD8 + T cell infiltration into either tumor stroma or total tumor. Localization into cancer islands within tumors is mediated by expression of the integrin CD103, which is a marker for tissue-resident memory T cells (TRMs). Analysis of fresh tumor samples revealed that CD8 + TRMs are functionally similar to other CD8 + TILs, suggesting that the basis of their protective effect is their spatial distribution rather than functional differences. Indeed, CD103 + TRMs, as compared with CD103 – CD8 + TILs, are enriched within cancer islands, and CD8 + TRM proximity to cancer cells drives the association of CD8 + TIL densities with RFS. Together, these findings reveal the importance of cancer island–localized CD8 + TRMs in surveillance of the breast tumor microenvironment and as a critical determinant of RFS in patients with breast cancer.
24 July 2024 in Cancer Immunology Research
Immune composition within the tumor microenvironment (TME) plays a central role in the propensity of cancer cells to metastasize and respond to therapy. Previous studies have suggested that the metastatic TME is immune-suppressed. However, limited accessibility to multiple metastatic sites within patients has made assessing the immune TME difficult in the context of multiorgan metastases. We utilized a rapid postmortem tissue collection protocol to assess the immune composition of numerous sites of breast cancer metastasis and paired tumor-free tissues. Metastases had comparable immune cell densities and compositions to paired tumor-free tissues of the same organ type. In contrast, immune cell densities in both metastatic and tumor-free tissues differed significantly between organ types, with lung immune infiltration being consistently greater than that in the liver. These immune profiling results were consistent between flow cytometry and multiplex immunofluorescence–based spatial analysis. Furthermore, we found that granulocytes were the predominant tumor-infiltrating immune cells in lung and liver metastases, and these granulocytes comprised most PD–L1–expressing cells in many tissue sites. We also identified distinct potential mechanisms of immunosuppression in lung and liver metastases, with the lung having increased expression of PD-L1+ antigen-presenting cells and the liver having higher numbers of activated regulatory T cells and HLA-DRlow monocytes. Together, these results demonstrate that the immune contexture of metastases is dictated by organ type and that immunotherapy strategies may benefit from unique tailoring to the tissue-specific features of the immune TME.